The role of CCL20/CCR6 axis in recruiting Treg cells to tumor sites of NSCLC patients

Biomedicine and Pharmacotherapy

Volumn 69, Issue , 2015, Pages 242-248

  Zhang, Chun yang ^a,b   Qi, Yu ^a   Li, Xiang nan ^a   Yang, Yang ^a   Liu, Dong lei ^a   Zhao, Jia ^a   Zhu, Deng yan ^a   Wu, Kai ^a   Zhou, Xu dong ^a   Zhao, Song ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b Key Laboratory of Thoracic Tumors of Zhengzhou   (China)

Author keywords

CCL20; Docetaxel; NSCLC

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR6; DOCETAXEL; INTERLEUKIN 10; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; CCL20 PROTEIN, HUMAN; CCR6 PROTEIN, HUMAN; TAXOID;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; DISEASE COURSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHEMOKINE CCL20; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; RECEPTORS, CCR6; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TAXOIDS;

EID: 84922228647     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.12.008     Document Type: Article

References (37)

1. Amoh Y., et al. Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis. Cancer Res 2005, 65(12):5352-5357.
2. Radzikowska E., Glaz P., Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20,561 cases. Ann Oncol 2002, 13(7):1087-1093.
3. Belani C.P., et al. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer 2014, 14:p290.
4. Wang Z., et al. Gene expression levels of CSNK1A1 and AAC-11, but not NME1, in tumor tissues as prognostic factors in NSCLC patients. Med Sci Monit 2010, 16(8):CR357-CR364.
5. Hoang T., Schiller J.H. Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy. Expert Rev Anticancer Ther 2002, 2(4):393-401.
6. Levina V., et al. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 2008, 123(9):2031-2040.
7. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12(2):121-127.
8. Mackay C.R. Chemokines: immunology's high impact factors. Nat Immunol 2001, 2(2):95-101.
9. Luther S.A., et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol 2002, 169(1):424-433.
10. Fiorenza S., et al. A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin. J Immunol 2012, 189(12):5622-5631.
11. Moser B., et al. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004, 25(2):75-84.
12. Bromley S.K., Mempel T.R., Luster A.D. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008, 9(9):970-980.
13. Loetscher P., Moser B. Homing chemokines in rheumatoid arthritis. Arthritis Res 2002, 4(4):233-236. [Epub 2002 Jan 31].
14. Parsonage G., et al. CXCR6 and CCR5 localize T lymphocyte subsets in nasopharyngeal carcinoma. Am J Pathol 2012, 180(3):1215-1222.
15. Patel D.D., Zachariah J.P., Whichard L.P. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001, 98(1):39-45.
16. Mirones I., et al. A role for the CXCR3/CXCL10 axis in Rasmussen encephalitis. Pediatr Neurol 2013, 49(6):451-457. e1.
17. Schutyser E., Struyf S., Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003, 14(5):409-426.
18. Cook K.W., et al. CCL20/CCR6-mediated migration of regulatory T cells to the Helicobacter pylori-infected human gastric mucosa. Gut 2014, 16(10). [2013-306253].
19. Frick V.O., et al. CCR6/CCL20 chemokine expression profile in distinct colorectal malignancies. Scand J Immunol 2013, 78(3):298-305.
20. Zuliani T., et al. Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: interests for adoptive immunotherapy. J Transl Med 2011, 9:p63.
21. Groeper C., et al. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer 2007, 120(2):337-343.
22. Turcotte S., et al. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res 2014, 20(2):331-343.
23. Harlin H., et al. Chemokine expression in melanoma metastases associated with CD8+T-cell recruitment. Cancer Res 2009, 69(7):3077-3085.
24. Winkler A.E., et al. CXCR3 enhances a T-cell-dependent epidermal proliferative response and promotes skin tumorigenesis. Cancer Res 2011, 71(17):5707-5716.
25. Wang L.H., Su L., Wang J.T. Correlation between elevated FOXP3 expression and increased lymph node metastasis of gastric cancer. Chin Med J (Engl) 2010, 123(24):3545-3549.
26. Nasman A., et al. Tumor infiltrating CD8+and Foxp3+lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One 2012, 7(6):p12.
27. Sakaguchi S., et al. FOXP3+regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10(7):490-500.
28. Chen M.L., et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A 2005, 102(2):419-424.
29. Wang Y., et al. Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. Cancer Res 2014, 74(8):2217-2228.
30. Eugenin E.A., Berman J.W. Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier. Methods 2003, 29(4):351-361.
31. Ransohoff R.M., Liu L., Cardona A.E. Chemokines and chemokine receptors: multipurpose players in neuroinflammation. Int Rev Neurobiol 2007, 82:187-204.
32. Chen D., et al. Chemokine/chemokine receptor interactions contribute to the accumulation of Th17 cells in patients with esophageal squamous cell carcinoma. Hum Immunol 2012, 73(11):1068-1072.
33. Wang D., et al. Modification of chemokine receptor expression to enhance levels of trafficking receptors on autologous cytokine-induced killer cells derived from patients with colorectal cancer. Biomed Pharmacother 2014, 68(5):551-556.
34. Chen B., et al. High CCR6/CCR7 expression and Foxp3+Treg cell number are positively related to the progression of laryngeal squamous cell carcinoma. Oncol Rep 2013, 30(3):1380-1390.
35. Liu J., et al. Tumor-associated macrophages recruit CCR6+regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One 2011, 6(4):pe19495.
36. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998, 338(7):436-445.
37. Tang Q., Bluestone J.A., Kang S.M. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol 2012, 4(1):11-21.